Mr. Daimon Glenn Parrotte, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 820 2nd St W, Havre, MT 59501 Phone: 406-265-4805 Fax: 406-265-4834 |
Spring-back Physical Therapy Llc Physical Therapist Medicare: Medicare Enrolled Practice Location: 309 3rd Ave, Havre, MT 59501 Phone: 406-945-9009 Fax: 406-945-9011 |
Ursula Mattson, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 820 2nd St W, Havre, MT 59501 Phone: 406-265-4805 |
Dr. Caroline Calabria, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1136 13th St W, Havre, MT 59501 Phone: 406-357-2549 |
Betty Boyce, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 820 2nd St W, Havre, MT 59501 Phone: 406-265-4805 Fax: 406-265-4834 |
News Archive
On the eve of its annual conference, leading doctors from the European Society of Hypertension have called for patient awareness and better clinician education to ensure more individualised treatment of high blood pressure.
"Throughout my tenure in the U.S. House of Representatives and on the Committee on Appropriations, I have had the opportunity to help shape U.S. development assistance. And I am proud of the United States' leadership in providing support and funding for critical global health initiatives that both save lives and strengthen our position in the world," Rep. Rosa DeLauro (D-Conn.) writes in The Hill's "Congress Blog."
A national Radiation Therapy Oncology Group (RTOG) study led by a Medical College of Wisconsin Cancer Center physician at Froedtert Hospital in Milwaukee has found that a course of radiation therapy to the brain after treatment for locally advanced non-small cell lung cancer reduced the risk of metastases to the brain within the first year after treatment. The study was presented at the American Society of Clinical Oncology annual meeting in Orlando, June 1.
Behavioral support from peers and primary care office staff can help patients improve their blood pressure control by as much as starting a new drug, a new study found. Barbara J. Turner, M.D., M.S.Ed., M.A., M.A.C.P., of UT Medicine San Antonio, is the senior author.
Two-year maintenance therapy with olaparib, a PARP (poly ADP ribose polymerase) inhibitor, olaparib, led to a substantial, unprecedented improvement in progression-free survival (PFS) in newly diagnosed patients with advanced ovarian cancer and a BRCA1 or 2 mutation, results from the phase 3 SOLO-1 trial show.
› Verified 7 days ago